Related Experiment Videos
Cost considerations surrounding current and future anticoagulant therapies
Margaret C Fang1, Tracy Minichiello, Andrew D Auerbach
1Department of Medicine Hospitalist Group, University of California, San Francisco, CA 94143-0131, USA.
Cleveland Clinic Journal of Medicine
|April 28, 2005
Summary
Economic analyses show anticoagulation therapy is most cost-effective for high-risk patients. More expensive anticoagulants are only cost-effective if they offer superior efficacy or reduce overall healthcare costs.
Area of Science:
- Pharmacoeconomics
- Clinical Decision-Making
- Thrombosis Management
Background:
- Anticoagulation therapy involves substantial costs.
- The risk-benefit balance of anticoagulation is often narrow.
- Economic evaluations are crucial for selecting anticoagulation strategies.
Purpose of the Study:
- To analyze the economic value of anticoagulation therapy.
- To guide clinical choices for anticoagulation based on cost-effectiveness.
Main Methods:
- Review of existing economic analyses on anticoagulation.
- Assessment of cost-effectiveness based on patient risk stratification.
- Evaluation of factors influencing the cost-effectiveness of newer anticoagulant agents.
Main Results:
- Anticoagulation is most effective and cost-saving in high-risk populations for thrombotic events.
- More expensive anticoagulants are cost-effective only if significantly more efficacious or if they reduce other healthcare costs (e.g., hospitalizations).
Conclusions:
- Economic principles should guide the selection of anticoagulation strategies.
- Targeting high-risk populations optimizes the cost-effectiveness of anticoagulation.
- Clinicians should consider overall efficacy and cost-reduction potential when choosing between anticoagulant agents.